Madrigal Pharmaceuticals/$MDGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Ticker
$MDGL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
528
ISIN
US5588681057
Website
MDGL Metrics
BasicAdvanced
$7B
-
-$17.97
-0.69
-
Price and volume
Market cap
$7B
Beta
-0.69
52-week high
$377.46
52-week low
$200.63
Average daily volume
294K
Financial strength
Current ratio
5.908
Quick ratio
5.438
Long term debt to equity
16.711
Total debt to equity
16.854
Interest coverage (TTM)
-30.09%
Profitability
EBITDA (TTM)
-423.842
Gross margin (TTM)
96.61%
Net profit margin (TTM)
-123.38%
Operating margin (TTM)
-133.95%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
-25.56%
Return on equity (TTM)
-50.16%
Valuation
Price to revenue (TTM)
21.607
Price to book
9.82
Price to tangible book (TTM)
9.89
Price to free cash flow (TTM)
-17.084
Free cash flow yield (TTM)
-5.85%
Free cash flow per share (TTM)
-1,841.72%
Growth
Earnings per share change (TTM)
-22.59%
3-year earnings per share growth (CAGR)
7.05%
What the Analysts think about MDGL
Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.
Bulls say / Bears say
Madrigal Pharmaceuticals' Rezdiffra has received conditional authorization from the European Union's drug regulator, positioning it as the first treatment for MASH in the EU, with a European launch planned starting in Germany later this year. (reuters.com)
Analysts have set an average 12-month target price of $375.75 for Madrigal Pharmaceuticals, indicating a potential upside from its current trading price. (marketbeat.com)
Rezdiffra's strong early market acceptance is evident, with prescription rates increasing from 30% in mid-2024 to 47% by early 2025, suggesting robust demand and potential for significant revenue growth. (investing.com)
Madrigal Pharmaceuticals reported a net loss of $391.59 million, reflecting ongoing financial challenges despite revenue growth. (fullratio.com)
The company's forward P/E ratio stands at -439.05, indicating projected losses and raising concerns about profitability. (directorstalkinterviews.com)
Potential competition from GLP-1 drugs, particularly tirzepatide, could challenge Rezdiffra's market position in the NASH treatment landscape. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
MDGL Financial Performance
Revenues and expenses
MDGL Earnings Performance
Company profitability
MDGL News
AllArticlesVideos
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
Market Watch·3 weeks ago
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewsWire·3 weeks ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Madrigal Pharmaceuticals stock?
Madrigal Pharmaceuticals (MDGL) has a market cap of $7B as of July 12, 2025.
What is the P/E ratio for Madrigal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Madrigal Pharmaceuticals (MDGL) stock is 0 as of July 12, 2025.
Does Madrigal Pharmaceuticals stock pay dividends?
No, Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Madrigal Pharmaceuticals dividend payment date?
Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) has a beta rating of -0.69. This means that it has an inverse relation to market volatility.